Pharmacogenomic Study of Patients with Depression
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective：Despite the availability of various antidepressants, clinicians managing depressed patients still face two challenges: 40-50% of patients will not respond sufficiently to acute treatment, and 2-6 weeks are required before a medication trial can be ruled a failure. Genetic factors contribute to the phenotype of drug response. The pharmacogenomic prediction of the antidepressant response is one possibility for improving the efficiency of antidepressant treatment. Methods：Monoamine transporters are the site of action of the most commonly used antidepressants. We established a depressive patient cohort and conducted a series of studies of the association between genetic polymorphisms in monoamine transporters and the antidepressant response. Results：We found specific associations between monoamine transporter polymorphisms and antidepressant responses, an ethnic difference in the association between 5-HTTLPR and selective serotonin reuptake inhibitors, and the predictive potential of combinations of polymorphisms. Conclusion：We have conducted pharmacogenomic studies of the antidepressant response for 12 years with the goal of increasing the treatment response to antidepressants for each individual depressed patient. This review summarizes our findings.
Abstract
Objective：Despite the availability of various antidepressants, clinicians managing depressed patients still face two challenges: 40-50% of patients will not respond sufficiently to acute treatment, and 2-6 weeks are required before a medication trial can be ruled a failure. Genetic factors contribute to the phenotype of drug response. The pharmacogenomic prediction of the antidepressant response is one possibility for improving the efficiency of antidepressant treatment. Methods：Monoamine transporters are the site of action of the most commonly used antidepressants. We established a depressive patient cohort and conducted a series of studies of the association between genetic polymorphisms in monoamine transporters and the antidepressant response. Results：We found specific associations between monoamine transporter polymorphisms and antidepressant responses, an ethnic difference in the association between 5-HTTLPR and selective serotonin reuptake inhibitors, and the predictive potential of combinations of polymorphisms. Conclusion：We have conducted pharmacogenomic studies of the antidepressant response for 12 years with the goal of increasing the treatment response to antidepressants for each individual depressed patient. This review summarizes our findings.
참고문헌 (27)
- Rush AJ, "Mood disorders: treatment of depression. In: Sadock BJ, Sadock VA, editors. Comprehensive Textbook of Psychiatry. 8th ed", pp.1652~1661 (2005), Lippincott Williams & Wilkins
- Thase ME, "Overview of antidepressant therapy", Manag Care, 10, pp.6~22 (2001)
- Serretti A, "From molecular biology to pharmacogen-etics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes", Psychopharmacology, 174, pp.490~503 (2004)
- Kirchheiner J, "Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response", Mol Psychiatry, 9, pp.442~473 (2004)
- Glatt CE, "Pharmacogenetics of monoamine transporters", Pharmacogenomics, 4, pp.583~596 (2003)
- Ramamoorthy S, "Antidepressant- and cocaine-sensitive human serotonin transporter; molecular cloning, expression, and chromosomal localization", Proc Natl Acad Sci U S A, 통권 : 90, pp.2542~2546 (1993)
- Lesch KP, "Organization of the human serotonin transporter gene", J Neural Transm, 95, pp.157~162 (1994)
- Ogilvie AD, "Polymorphism in serotonin transporter gene associated with susceptibility to major depression", Lancet, 347, pp.731~733 (1996)
- Heils A, "Allelic variation of human serotonin transporter gene expression", J Neurochem, 66, pp.2621~2624 (1996)
- Lesch K, "Greenberg BD, Petri S, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region", Science, 274, pp.1527~1530 (1996)
- Hamilton M, "Development of a rating scale for primary depressive illness", Br J Soc Clin Psychol, 6, pp.278~296 (1967)
- Guy W, "CGI Clinical Global Impressions. In: ECDEU Assessment Manual for Psychopharmacology", pp.217~222 (1976), National Institute of Mental Health, NIMH
- Kim DK, "Serotonin transporter gene polymorphism and antidepressant response", NeuroReport, 11, pp.215~219 (2000)
- Smeraldi E, "Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine", Mol Psychiatry, 3, pp.508~511 (1998)
- Pollock BG, "Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in latelife depression", Neuropsychopharmacology, 23, pp.587~590 (2000)
- Durham LK, "The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder", Psychopharmacol, 174, pp.525~529 (2004)
- Rausch JL, "Initial conditions of serotonin transporter kinetics and genotype; influence on SSRI treatment trial outcome", Biol Psychiatry, 51, pp.723~732 (2002)
- Yoshida K, "Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients", Prog Neuropsychopharmacol Biol Psychiatry, 26, pp.383~386 (2002)
- Nakamura M, "The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants", Mol Psychiatry, 5, pp.32~38 (2000)
- Gelernter J, "Serotonin transporter protein (SCL6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects", Hum Genet, 101, pp.243~246 (1997)
- Bellivier F, "Serotonin transporter gene polymorphisms in patients with unipolar or bipolar depression", Neurosci Lett, 255, pp.143~146 (1998)
- Fredman SJ, "Partial response, nonresponse, and relapse with selective serotonin reuptake inhibitors in major depression; a survey of current “next-step” practice", J Clin Psychiatry, 61, pp.403~408 (2000)
- Anderson IM, "Selective serotonin reuptake inhibitors versus tricyclic antidepressants; a meta-analysis of efficacy and tolerability", J Affect Disord, 58, pp.19~36 (2000)
- Lesch KP, "Primary structure of the human platelet serotonin uptake site: identity with the brain serotonin transporter", J Neurochem, 60, pp.2319~2322 (1993)
- Kim DK, "Serotonin transporter gene polymorphism in depression: clinical, functional and ethnic phenotypic correlates", Proceedings of the 12th World Congress of Psychiatry (2002)
- Greenberg BD, "Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets", Am J Med Genet, 88, pp.83~87 (1999)
- Kim H, "Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression", JAMA, 296, pp.1609~1618 (2006)